Lukasz K. Chlewicki

2.3k citations

15 papers · 1.7k indexed · 2 hit papers · h-index 10

Immunology top 2%
- T-cell and B-cell Immunology 11
- Immune Cell Function and Interaction 9
- Immunotherapy and Immune Responses 4
- Biosimilars and Bioanalytical Methods 2
Oncology top 2%
- CAR-T cell therapy research 4
- Cancer Immunotherapy and Biomarkers 2
Radiology, Nuclear Medicine and Imaging top 10%
- Monoclonal and Polyclonal Antibodies Research 5
Biotechnology top 10%
Cancer Research
Molecular Biology
- vaccines and immunoinformatics approaches 2

Co-authors: Yang‐Xin Fu David M. Kranz Byron Burnette Youjin Lee Nikolai N. Khodarev Ralph R. Weichselbaum Sogyong Auh Hua Liang
Cited by: Immunology Oncology Radiology, Nuclear Medicine and Imaging
Partner nations: United States Italy Germany

In The Last Decade

Lukasz K. Chlewicki

13 papers receiving 1.7k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2016 Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
2011 The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon–Dependent Innate and Adaptive Immunity

Peers

Countries citing papers authored by Lukasz K. Chlewicki

Since Specialization

Citations

This map shows the geographic impact of Lukasz K. Chlewicki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lukasz K. Chlewicki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lukasz K. Chlewicki more than expected).

Fields of papers citing papers by Lukasz K. Chlewicki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lukasz K. Chlewicki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lukasz K. Chlewicki. The network helps show where Lukasz K. Chlewicki may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Lukasz K. Chlewicki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lukasz K. Chlewicki Line = papers co-authored together Lukasz K. Chlewicki links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work
1	Immunogenicity Risk Assessment of Biotherapeutics Using an Ex Vivo B Cell Assay Kevin M. Budge,Ross L. Blankenship,Patricia Brown‐Augsburger,Lukasz K. Chlewicki	2025	0
2	Generation and Characterization of Torudokimab (LY3375880): A Monoclonal Antibody That Neutralizes Interleukin-33 Angela J. Okragly,Katie Brannon Corwin,Marikka Elia,Dongmei He,Oliver C. Schroeder,Qing Zhang,Tatiyana L. Shiyanova,Stuart W. Bright,Sarah B Dicker,Lukasz K. Chlewicki,Stephanie M.E. Truhlar,Julian Davies,Chetan N. Patel,Robert J. Benschop	2021	9
3	Validation of a de‐immunization strategy for monoclonal antibodies using cynomolgus macaque as a surrogate for human Natalia Kovalova,Jeffrey S. Boyles,Yi Wen,Derrick R. Witcher,Patricia Brown‐Augsburger,Victor J. Wroblewski,Lukasz K. Chlewicki	2020	1
4	Correlation between antidrug antibodies, pre-existing antidrug reactivity, and immunogenetics (MHC class II alleles) in cynomolgus macaque Natalia Kovalova,Michael D. Knierman,Patricia Brown‐Augsburger,Victor J. Wroblewski,Lukasz K. Chlewicki	2019	4
5	Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockadebreakdown → Haidong Tang,Yang Wang,Lukasz K. Chlewicki,Yuan Zhang,Jingya Guo,Wei Liang,Jieyi Wang,Xiaoxiao Wang,Yang‐Xin Fu	2016	382
6	Engagement of NK receptor NKG2D, but not 2B4, results in self-reactive CD8+T cells and autoimmune vitiligo Andrew Zloza,Gretchen E. Lyons,Lukasz K. Chlewicki,Frederick J. Kohlhapp,Jeremy A. O’Sullivan,Andrew T. Lacek,Tamson V. Moore,Michael C. Jagoda,Vinay Kumar,José A. Guevara-Patiño	2011	18
7	The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon–Dependent Innate and Adaptive Immunitybreakdown → Byron Burnette,Hua Liang,Youjin Lee,Lukasz K. Chlewicki,Nikolai N. Khodarev,Ralph R. Weichselbaum,Yang‐Xin Fu,Sogyong Auh	2011	686
8	Engineering the binding properties of the T cell receptor:peptide:MHC ternary complex that governs T cell activity Natalie A. Bowerman,Terence S. Crofts,Lukasz K. Chlewicki,Priscilla Do,Brian M. Baker,K. Christopher García,David M. Kranz	2009	30
9	Structure of Natural Killer Cell Receptor KLRG1 Bound to E-Cadherin Reveals Basis for MHC-Independent Missing Self Recognition Yili Li,Maike Hofmann,Qian Wang,Leslie Teng,Lukasz K. Chlewicki,Hanspeter Pircher,Roy A. Mariuzza	2009	83
10	A Model System for Studying NK Cell Receptor Signaling Lukasz K. Chlewicki,Vinay Kumar	2009	0
11	Molecular Basis of the Dual Functions of 2B4 (CD244) Lukasz K. Chlewicki,Carlos A. Velikovsky,Vamsi Balakrishnan,Roy A. Mariuzza,Vinay Kumar	2008	115
12	Structure of Natural Killer Receptor 2B4 Bound to CD48 Reveals Basis for Heterophilic Recognition in Signaling Lymphocyte Activation Molecule Family Carlos A. Velikovsky,Lu Deng,Lukasz K. Chlewicki,Marisa M. Fernández,Vinay Kumar,Roy A. Mariuzza	2007	46
13	High-affinity, Peptide-specific T Cell Receptors can be Generated by Mutations in CDR1, CDR2 or CDR3 Lukasz K. Chlewicki,Phillip D. Holler,Bridget C. Monti,Matthew R. Clutter,David M. Kranz	2004	76
14	Variable MHC class I engagement by Ly49 natural killer cell receptors demonstrated by the crystal structure of Ly49C bound to H-2Kb Julie Dam,Rongjin Guan,Kannan Natarajan,Nazzareno Dimasi,Lukasz K. Chlewicki,David M. Kranz,Peter Schuck,David H. Margulies,Roy A. Mariuzza	2003	108
15	TCRs with high affinity for foreign pMHC show self-reactivity Phillip D. Holler,Lukasz K. Chlewicki,David M. Kranz	2002	179

About Lukasz K. Chlewicki

Lukasz K. Chlewicki is a scholar working on Immunology, Radiology, Nuclear Medicine and Imaging and Oncology, having authored 15 papers that have together received 1.7k indexed citations. Recurring topics across this work include T-cell and B-cell Immunology (11 papers), Immune Cell Function and Interaction (9 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), CAR-T cell therapy research (4 papers), Immunotherapy and Immune Responses (4 papers), vaccines and immunoinformatics approaches (2 papers), Biosimilars and Bioanalytical Methods (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). The work is most often cited by research in Immunology (1.3k citations), Oncology (987 citations) and Radiology, Nuclear Medicine and Imaging (205 citations). Lukasz K. Chlewicki has collaborated with scholars based in United States, Italy and Germany. Frequent co-authors include Yang‐Xin Fu, David M. Kranz, Byron Burnette, Youjin Lee, Nikolai N. Khodarev, Ralph R. Weichselbaum, Sogyong Auh, Hua Liang, Phillip D. Holler and Roy A. Mariuzza.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact